Linaclotidea stimulating new drug for chronic constipation

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 7, 2010, Pages 365-366

  Harris, Lucinda A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE ACTIVATOR; LACTULOSE; LINACLOTIDE; LUBIPROSTONE; MACROGOL; PLACEBO; PRUCALOPRIDE; TEGASEROD; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR RECEPTOR; PEPTIDE;

ABDOMINAL DISCOMFORT; BLOATING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DEFECATION HABIT; DIARRHEA; DIETARY FIBER; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INTESTINE FLUID; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BINDING; RECEPTOR UPREGULATION; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; CHRONIC DISEASE; DRUG POTENTIATION; NOTE;

CHRONIC DISEASE; CONSTIPATION; HUMANS; PEPTIDES; RECEPTORS, GUANYLATE CYCLASE-COUPLED; TREATMENT OUTCOME;

EID: 77955836964     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.84     Document Type: Short Survey

References (9)

1. Brandt, L. J. et al. systematic review on the management of chronic constipation in north America. Am. J. Gastroenterol. 100 (suppl. 1), s5-s21 (2005).
2. sonnenberg, A. and Koch, T. R. Physician visits in the United states for constipation: 1958- 1986. Dig. Dis. Sci. 34, 606-611 (1989). (Pubitemid 19122000)
3. schiller, L. R. and Johnson, D. A. Balancing drug risk and benefit: toward redefining the process of FDA decisions affecting patient care. Am. J. Gastroenterol. 103, 815-819 (2008).
4. Crowell, M. D., Harris, L. A., Lunsford, T. n. and Dibaise, J. K. emerging drugs for chronic constipation. Expert Opin. Emerg. Drugs 14, 493-504 (2009).
5. Currie, M. G. et al. effects of a single dose administration of MD-1100 on safety, tolerability, exposure and stool consistency in healthy subjects. Am. J. Gastroenterol. 100 (suppl.), s328 (2005).
6. Andresen, v. et al. effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133, 761-768 (2007).
7. Lembo, A. J. et al. efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138, 886-895 (2010).
8. Chang, L. and Drossman, D. A. Rome Foundation endpoints and Outcomes Conference 2009: optimizing clinical trials in FGiD. Am. J. Gastroenterol. 105, 722-730 (2010).
9. Trentacosti, A. M., He, R., Burke, L. B., Griebel, D. and Kennedy, D. L. evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am. J. Gastroenterol. 105, 731-735 (2010).